Dysregulated Metabolic Cell Cycle Checkpoints in Human Cancer The decision by a cell to divide or enter quiescence is made in early G1 after mitosis. Cells need instructions from growth factors to continue cycling through G1 into S-phase. In the absence of appropriate growth factor signals, cells enter a resting quiescent state referred to as G0. The site in G1 where growth factor signals are required has been mapped to a site early in G1. This site is commonly referred to as the Restriction Point (R). However, many reports describe R as a site much later in G1 where the cell makes a final commitment to replicate its DNA and divide. This site resembles a site in the yeast cell cycle known as START. However, START is dependent upon nutrient sufficiency rather than growth factors. We are proposing a set of metabolic checkpoints late in G1 that are dependent on nutrient input prior to committing to replicate the genome and dividing. This late G1 cell cycle control site is likely integrated into signals mediated by mTOR - the mammalian target of rapamycin, which senses nutrient and energy sufficiency. We hypothesize that these late G1 cell cycle control sites collectively represent a """"""""Cell Growth"""""""" checkpoint where levels of essential nutrients are evaluated prior to committing to doubling in mass and replicating the genome. It is proposed that these metabolic checkpoints, along with R, need to be dysregulated in virtually all human cancers and that complementary genetic changes in human cancer cells cooperate to overcome both R and the Cell Growth checkpoints. This study addresses long-running misconceptions about of G1 cell cycle progression and investigates the feasibility of therapeutic exploitation of dysregulated cell cycle checkpoints in human cancers. The Central Hypothesis of the proposal is that there are Metabolic Cell Cycle Checkpoints late in G1 that can be distinguished from the growth factor-dependent Restriction Point (R). Thus, cells decide first whether they should divide at R, and then prior to replicating the genome, they decide whether they are capable of dividing at a set of Metabolic Cell Growth checkpoints that monitor nutrient sufficiency. It is proposed that mTOR is the final arbiter of whether to commit to replicating the genome and dividing. A series of experiments are proposed that will: 1) Distinguish the impact of growth factors, nutrients and mTOR on G1 cell cycle progression - most significantly, a newly identified lipid-sensitive G1 checkpoint;2) Distinguish requirements of cells for G1 cell cycle progression when originating from mitosis or from quiescence;and 3) Characterize cell cycle checkpoint(s) mediated by glutamine and evaluate the feasibility of therapeutically exploiting dysregulated checkpoints in human cancer cell lines. Many of the signals that promote progression through late G1 of the cell cycle are commonly referred to as """"""""survival signals"""""""" because they suppress apoptotic programs that kick in if the cell is not capable of replicating the genome and dividing. These signals are ideal targets for therapeutic intervention because, in principle, suppression of survival signals leads to either apoptosis or senescence. This study will investigate a proposed set of Metabolic checkpoints in late G1 that are overcome by survival signals in virtually all cancer cells. Therefore, the study will have relevance - and impact - for a large percentage of human cancers because of the need to dysregulate the control of progression through late G1 and avoid the cell death and senescence programs that prevent cancer.
A Dysregulated Metabolic Cell Cycle Checkpoints in Human Cancer Relevance: Many of the signals that promote progression through late G1 of the cell cycle are commonly referred to as survival signals. These signals are ideal targets for therapeutic intervention because, in principle, suppression of survival signals will reverse survival and lead to apoptosis or senescence. This study will investigate proposed Cell Growth checkpoints in late G1 that are overcome by survival signals in virtually all cancer cells. Therefore, the study will have relevance for a large percentage of human cancers because of the need to dysregulate the control of progression through late G1 and avoid the cell death and senescence programs that prevent cancer.
|Utter, Matthew; Chakraborty, Sohag; Goren, Limor et al. (2018) Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes. Cancer Lett 423:28-35|
|Bernfeld, Elyssa; Menon, Deepak; Vaghela, Vishaldeep et al. (2018) Phospholipase D-dependent mTOR complex 1 (mTORC1) activation by glutamine. J Biol Chem 293:16390-16401|
|Patel, Deven; Salloum, Darin; Saqcena, Mahesh et al. (2017) A Late G1 Lipid Checkpoint That Is Dysregulated in Clear Cell Renal Carcinoma Cells. J Biol Chem 292:936-944|
|Menon, Deepak; Salloum, Darin; Bernfeld, Elyssa et al. (2017) Lipid sensing by mTOR complexes via de novo synthesis of phosphatidic acid. J Biol Chem 292:6303-6311|
|Patel, Deven; Menon, Deepak; Bernfeld, Elyssa et al. (2016) Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells. J Biol Chem 291:9322-9|
|Mukhopadhyay, Suman; Frias, Maria A; Chatterjee, Amrita et al. (2016) The Enigma of Rapamycin Dosage. Mol Cancer Ther 15:347-53|
|Saqcena, Mahesh; Patel, Deven; Menon, Deepak et al. (2015) Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle. Cell Cycle 14:2285-92|
|Mukhopadhyay, Suman; Chatterjee, Amrita; Kogan, Diane et al. (2015) 5-Aminoimidazole-4-carboxamide-1-?-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. Cell Cycle 14:3331-9|
|LeGendre, Onica; Breslin, Paul As; Foster, David A (2015) (-)-Oleocanthal rapidly and selectively induces cancer cell death via lysosomal membrane permeabilization. Mol Cell Oncol 2:e1006077|
|Mukhopadhyay, Suman; Saqcena, Mahesh; Chatterjee, Amrita et al. (2015) Reciprocal regulation of AMP-activated protein kinase and phospholipase D. J Biol Chem 290:6986-93|
Showing the most recent 10 out of 13 publications